Portal de Periódicos da CAPES

Cerebrospinal fluid level of neurofilament light chain is associated with increased disease activity in neuro-Behçet's disease

2022; Scientific and Technological Research Council of Turkey (TUBITAK); Volume: 52; Issue: 4 Linguagem: Inglês

10.55730/1300-0144.5432

1303-6165

Zerrin Karaaslan, Elif Şanlı, ÖZLEM TİMİRCİ KAHRAMAN, VUSLAT YILMAZ, Ece Akbayır, Gizem Koral, SEMA İÇÖZ, Tuncay Gündüz, CEM İSMAİL KÜÇÜKALİ, MURAT KÜRTÜNCÜ, ERDEM TÜZÜN,

Autoimmune and Inflammatory Disorders Research

Clinical exacerbations characterized with neurological symptoms are observed in around 10% of Behçet's disease (BD) patients and may culminate in severe disability. Although certain immunological factors have been associated with disease activity in neuro-Behçet's disease (NBD), biomarkers for monitoring the clinical outcome of NBD have not been properly investigated.Levels of neurofilament light chain (NFL), homeobox protein Hox-B3 (HoxB3), and YKL-40 were measured in cerebrospinal fluid (CSF) samples of 23 parenchymal (n = 16) and nonparenchymal (n = 7) NBD patients obtained during NBD attacks by ELISA. Parameters of clinical progression and outcome were assessed for an average follow-up period of 3.9 ± 1.3 years.Parenchymal NBD patients showed elevated CSF levels of NFL, HoxB3, and YKL-40 as compared to nonparenchymal patients. NBD patients showing an increase in modified Rankin score (mRS) values during follow-up had significantly higher CSF NFL levels. Patients with relatively lower CSF NFL levels (<1000 ng/L) did not develop attacks or cognitive impairment interfering with daily life activities during follow-up. NFL levels correlated with disease duration and mRS at the last follow-up visit, while HoxB3 levels correlated with a number of attacks during follow-up.CSF level of NFL appears to predict the prospective somatic and cognitive disability in NBD patients and may thus be potentially used as a biomarker of clinical outcome in this disease.